OmniActive Health Technologies, the North American marketer of ENovate Biolife's enXtra, has announced the outcomes of a new study — A Randomized, Placebo-Controlled Clinical Trial Demonstrating Safety & Efficacy of enXtra in Healthy Adults — which was published in the Journal of the American College of Nutrition.
"The latest study demonstrates our commitment to support on-trend claims with credible science for our global customers," said JayeshChaudhary, founder and CEO of ENovate Biolife.
"Whether it's using computerised Attention Network Test, molecular docking studies or assessing longer-term cardiogenic safety, we rely on cutting-edge research tools that are setting new benchmarks in our industry."
The 12-week double-blind, randomised, placebo-controlled, parallel-group study was conducted on adults who reported moderate caffeine consumption.
Subjects were randomised to receive either enXtra, enXtra plus caffeine or a placebo. The findings of the study demonstrate that enXtra — either alone or in combination with caffeine — exerts a psychostimulant effect (alertness), exhibits no safety concerns with long-term use and strengthens earlier findings supporting its nootropic benefits.
During the course of the entire study, enXtra displayed an acute and consistent improvement in alertness, which suggests a lack of habituation (subjects do not have to take increasing doses of enXtra to exert a similar effect).
The study provides finished product manufacturers a clinically demonstrated safe and effective ingredients to fill a much-needed gap in the energy market.
"With more than 50% of consumers reporting that their energy levels have worsened in the last 10 years, the market for healthy energy will continue to grow in the supplement space," said Arti Shah, Executive Vice President of Global Marketing.
"enXtra provides a unique solution for formulators who are increasingly looking for natural, safe and clinically tested ingredients to grow their energy portfolio and stand out in a crowded marketplace."